We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Aegerion Pharmaceuticals' Myalepta, a treatment for the ultra-rare condition lipodystrophy, has been approved by the EC as an adjunct to diet as a replacement therapy to treat the complications of leptin deficiency in lipodystrophy patients.